What the FDA labels say about taking them together
Digoxin and indomethacin
Digoxin's FDA label of December 5, 2024 names indomethacin in its drug interactions section, and indomethacin's label names digoxin too. The indomethacin label: “The concomitant use of INDOCIN with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the indomethacin FDA label on DailyMed (effective December 19, 2025, Glenmark Pharmaceuticals Inc., USA).
What does the digoxin label say about indomethacin?
Digoxin label, drug interactionsIndomethacin; 40%; NA; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring.
Source: FDA drug label (Digoxin, NDA021648), Hikma Pharmaceuticals USA Inc., effective April 10, 2025 (SPL set 1b7e5c6e-e052-41b0-a4ce-05dfe62faaaf), via openFDA
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the indomethacin label say about digoxin?
Indomethacin label, drug interactionsClinical Impact: The concomitant use of indomethacin with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Intervention: During concomitant use of indomethacin capsules and digoxin, monitor serum digoxin levels.
Indomethacin label (Chartwell RX, LLC, March 26, 2025), drug interactionsDigoxin Indomethacin given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
Indomethacin label (Fresenius Kabi USA, LLC, January 19, 2026), drug interactionsWhen used concomitantly with digoxin, monitor neonates for the development of digoxin toxicity.
Source: FDA drug label (Indomethacin, NDA018829), Chartwell RX, LLC, effective March 26, 2025 (SPL set 9607920c-4d25-40b9-957e-87e9ca5574e8), via openFDA
Source: FDA drug label (Indomethacin, NDA022536), Fresenius Kabi USA, LLC, effective January 19, 2026 (SPL set ec482425-358c-4500-8f5d-79c1379c1fa8), via openFDA
Source: FDA drug label (Indocin, NDA018332), Zyla Life Sciences US LLC, effective December 16, 2024 (SPL set 73878376-1d24-423b-9f37-3666e83c95da), via openFDA
Source: FDA drug label (Indomethacin), Glenmark Pharmaceuticals Inc., USA, effective December 19, 2025 (SPL set f7ed39e2-5431-4e47-935c-c7441d058f94), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Indomethacin | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Rheumatoid arthritis, Osteoarthritis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | $0.210 per capsule 75 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once